BB Biotech AG publishes its interim report
Media Release, April 23, 2021
BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2021, which covers the results of its business activities for the first three months of 2021.
Based on the consolidated accounts of BB Biotech AG, net profit for the period ended March 31, 2021 amounted to CHF 221 mn (loss of CHF 758 mn in the same period 2020). For an investment company, the results reflect the share price development of the companies held in the portfolio.
For further information: Bellevue Asset Management AG, Seestrasse 16, 8700 K?snacht, Switzerland Tanja Chicherio, Tel. +41 44 267 67 07, firstname.lastname@example.org
Company profile BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in Switzerland, Germany and Italy. Since 1993, the company has invested in innovative drug development companies that are mainly located in the US and Western Europe. BB Biotech AG is one of the leading investors in this sector. BB Biotech AG builds on the long-standing experience of its distinguished Board of Directors and on the fundamental analysis of the experienced Investment Management Team of Bellevue Asset Management AG when making its investment decisions.
23-Apr-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English Company: BB BIOTECH AG Schwertstrasse 6 8200 Schaffhausen
Switzerland Phone: +41 52 624 08 45 E-mail: email@example.com Internet: www.bbbiotech.ch ISIN: CH0038389992 WKN: A0NFN3 Listed: Regulated Market in Frankfurt (Prime Standard); Mailand, SIX EQS News ID: 1187763 ? End of Announcement DGAP News Service